Beyond the cell: redefining mesenchymal stem cell therapy through the secretome—comparative efficacy, molecular mechanisms, and future directions in cell-free therapy

For decades, Mesenchymal Stem Cells (MSCs) were hailed as the “foundational mediators” of regenerative medicine, presumed to physically rebuild damaged tissues through engraftment and differentiation. However, a fundamental conceptual advancement has revealed that the true therapeutic power lies not in the cell, but in the molecular signaling mediators they distribute. We now understand that the “secretome” — a sophisticated, paracrine cloud of soluble proteins, bioactive lipids, and extracellular vesicles (EVs) — is the principal mechanism of therapeutic action. We delve into the critical role of “licensing”, illustrating how environmental cues and pro-inflammatory priming act as metabolic switches that transform a resting cell’s output into a targeted therapeutic tool. To decode this biological complexity, we argue that the field must move beyond standard assays and embrace an integration of high-throughput multi-omic analysis. We synthesize the integration of high-throughput Mass Spectrometry with the ultra-sensitivity of next-generation affinity platforms (Olink, Illumina) and single-cell transcriptomics, enabling us to map the lineage of a therapeutic protein from its genomic instruction to its vesicular release. Furthermore, we highlight how Artificial Intelligence and Machine Learning are finally allowing us to solve the “challenge of cellular heterogeneity”, moving from trial-and-error to algorithmic prediction of donor potency. Ultimately, this comprehensive analysis offers a strategic framework for the future: a shift toward scalable, GMP-compliant manufacturing where the MSC secretome is no longer an elusive biological phenomenon, but a standardized, off-the-shelf precision medicine.

Authors

Publication Details

Journal
Journal of Translational Medicine
Published
2026-11-18
DOI
https://doi.org/10.1186/s12967-026-09243-2
Primary Topic
Mesenchymal stem cell research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Beyond the cell: redefining mesenchymal stem cell therapy through the secretome—comparative efficacy, molecular mechanisms, and future directions in cell-free therapy

Vijay Mahant, Annette M. Marleau, Erik C. Hett, Edward Clay et al.
Journal of Translational Medicine
Mesenchymal stem cell research
article

Beyond the cell: redefining mesenchymal stem cell therapy through the secretome—comparative efficacy, molecular mechanisms, and future directions in cell-free therapy

Vijay Mahant, Annette M. Marleau, Erik C. Hett, Edward Clay, Patricia Juárez, Francesco M. Marincola, Ali Asadi, Thomas E. Ichim, Diego Guerena, JOYCE HU, Jando Fahme, Carlo A. Vargas
article en

Abstract

For decades, Mesenchymal Stem Cells (MSCs) were hailed as the “foundational mediators” of regenerative medicine, presumed to physically rebuild damaged tissues through engraftment and differentiation. However, a fundamental conceptual advancement has revealed that the true therapeutic power lies not in the cell, but in the molecular signaling mediators they distribute. We now understand that the “secretome” — a sophisticated, paracrine cloud of soluble proteins, bioactive lipids, and extracellular vesicles (EVs) — is the principal mechanism of therapeutic action. We delve into the critical role of “licensing”, illustrating how environmental cues and pro-inflammatory priming act as metabolic switches that transform a resting cell’s output into a targeted therapeutic tool. To decode this biological complexity, we argue that the field must move beyond standard assays and embrace an integration of high-throughput multi-omic analysis. We synthesize the integration of high-throughput Mass Spectrometry with the ultra-sensitivity of next-generation affinity platforms (Olink, Illumina) and single-cell transcriptomics, enabling us to map the lineage of a therapeutic protein from its genomic instruction to its vesicular release. Furthermore, we highlight how Artificial Intelligence and Machine Learning are finally allowing us to solve the “challenge of cellular heterogeneity”, moving from trial-and-error to algorithmic prediction of donor potency. Ultimately, this comprehensive analysis offers a strategic framework for the future: a shift toward scalable, GMP-compliant manufacturing where the MSC secretome is no longer an elusive biological phenomenon, but a standardized, off-the-shelf precision medicine.

Journal of Translational Medicine
Good health and well-being
Mesenchymal stem cell research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon